Insulin resistance arises when the nutrient storage pathways evolved to maximize efficient energy utilization are exposed to chronic energy surplus. Ectopic lipid accumulation in liver and skeletal muscle triggers pathways that impair insulin signaling, leading to reduced muscle glucose uptake and decreased hepatic glycogen synthesis. Muscle insulin resistance, due to ectopic lipid, precedes liver insulin resistance and diverts ingested glucose to the liver, resulting in increased hepatic de novo lipogenesis and hyperlipidemia. Subsequent macrophage infiltration into white adipose tissue (WAT) leads to increased lipolysis, which further increases hepatic triglyceride synthesis and hyperlipidemia due to increased fatty acid esterification. Macrophage-induced WAT lipolysis also stimulates hepatic gluconeogenesis, promoting fasting and postprandial hyperglycemia through increased fatty acid delivery to the liver, which results in increased hepatic acetyl-CoA content, a potent activator of pyruvate carboxylase, and increased glycerol conversion to glucose. These substrate-regulated processes are mostly independent of insulin signaling in the liver but are dependent on insulin signaling in WAT, which becomes defective with inflammation. Therapies that decrease ectopic lipid storage and diminish macrophage-induced WAT lipolysis will reverse the root causes of type 2 diabetes.
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux

Varman T. Samuel1,2 and Gerald I. Shulman1,3,4

1Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. 2Veterans Affairs Medical Center, West Haven, Connecticut, USA. 3Department of Cellular and Molecular Physiology and 4Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA.

Insulin resistance arises when the nutrient storage pathways evolved to maximize efficient energy utilization are exposed to chronic energy surplus. Ectopic lipid accumulation in liver and skeletal muscle triggers pathways that impair insulin signaling, leading to reduced muscle glucose uptake and decreased hepatic glycogen synthesis. Muscle insulin resistance, due to ectopic lipid, precedes liver insulin resistance and diverts ingested glucose to the liver, resulting in increased hepatic de novo lipogenesis and hyperlipidemia. Subsequent macrophage infiltration into white adipose tissue (WAT) leads to increased lipolysis, which further increases hepatic triglyceride synthesis and hyperlipidemia due to increased fatty acid esterification. Macrophage-induced WAT lipolysis also stimulates hepatic gluconeogenesis, promoting fasting and postprandial hyperglycemia through increased fatty acid delivery to the liver, which results in increased hepatic acetyl-CoA content, a potent activator of pyruvate carboxylase, and increased glycerol conversion to glucose. These substrate-regulated processes are mostly independent of insulin signaling in the liver but are dependent on insulin signaling in WAT, which becomes defective with inflammation. Therapies that decrease ectopic lipid storage and diminish macrophage-induced WAT lipolysis will reverse the root causes of type 2 diabetes.

In most natural habitats, calorie availability is scarce and unpredictable, necessitating the evolution of systems for the efficient storage and utilization of energy. But in our modern, mechanized society, caloric demands are minimized, while highly palatable, calorie-dense foods and beverages are readily available. These changes have fostered the current pandemic of obesity and comorbid conditions of nonalcoholic fatty liver disease (NAFLD), atherosclerosis, and type 2 diabetes (T2D). Insulin resistance is a common feature of all these diseases, and much effort has been invested in delineating the pathogenesis of insulin resistance. We will first review the role of insulin and nutrients (specifically glucose and fatty acids) in nutrient storage (Figure 1) and then use this framework to explore the various defects that give rise to insulin resistance and T2D (Figure 2).

Postprandial hepatic glucose and lipid metabolism

The simple act of eating rapidly shifts hepatic glucose metabolism from glucose production to glucose storage, a complex transition regulated by multiple factors including nutrients, alterations in pancreatic and enteric hormones, and neural regulation. Insulin is a crucial regulator of this transition, primarily by activating glycogen synthase (1). The importance of insulin is seen in patients with type 1 diabetes (T1D), who only synthesize one-third the amount of hepatic glycogen as control subjects after a mixed meal (2). Yet, hyperinsulinemia, in the absence of hyperglycemia, promotes hepatic glycogen cycling with minimal net hepatic glycogen synthesis (1). And hyperglycemia, without hyperinsulinemia, inhibits hepatic glycogenolysis via glucose-mediated inhibition of glycogen phosphorylase (3), with minimal net hepatic glycogen synthesis (1). The combination of hyperinsulinemia and hyperglycemia maximizes net hepatic glycogen synthesis (1). Other nutrients further optimize net hepatic glycogen synthesis, such as activation of glucokinase by catalytic quantities of fructose (4).

Hepatic insulin action requires a coordinated relay of intracellular signals (Figure 1 and ref. 5). Insulin activates the insulin receptor tyrosine kinase (IRTK), with subsequent activation of kinases including 3-phosphoinositide-dependent kinase-1 (PDK1) and mTORC2 (6), which converge on Akt phosphorylation (6–8). The pattern of insulin delivery may also impact Akt phosphorylation, with pulsatile portal delivery (which better mimics physiology) leading to greater activation than continuous, fixed insulin delivery (9). Activation of Akt is the integral result of multiple inputs to regulate hepatic glucose and lipid metabolism. This model has been used to explain how insulin suppresses hepatic glucose production via (i) lowering expression of gluconeogenic enzymes via phosphorylation and nuclear exclusion of FOXO1 and (ii) inactivation of glycogen synthase kinase 3β (GSK3β), which permits the activation of glycogen synthase.

Recent studies challenge the primacy of the Akt/GSK3β/glycogen synthase branch in the regulation of glycogen synthesis (10). Hepatic insulin resistance in mice lacking both hepatic Akt1 and Akt2 (double liver KO; DLKO) was essentially normalized by the additional deletion of FOXO1, in a triple KO (TLKO) mouse model (11). Remarkably, the TLKO mice exhibited relatively normal fasting and postprandial glucose tolerance (10). This suggests that FOXO1 deletion enables other mechanisms to normalize hepatic glucose metabolism. Finally, Akt2-mediated

Conflict of interest: The authors have declared that no conflict of interest exists.

The suppression of hepatic glucose production after meals (12, 13). In a canine study, raising portal insulin eight-fold — while keeping plasma glucose and glucagon concentrations fixed — lowered hepatic glucose production within 30 minutes but did not reduce protein expression of gluconeogenic enzymes. Two hours of sustained hyperinsulinemia were required to detect a modest decline in protein (14). More than 50 years ago, Levine and Fritz proposed that insulin inhibited hepatic glucose production through an indirect mechanism (15). Bergman and others postulated that insulin’s ability to suppress hepatic glucose production was linked to the suppression of adipose lipolysis (16). Recent studies by Perry et al. provide a molecular mechanism linking insulin action in white adipose tissue (WAT) to the regulation of hepatic gluconeogenesis (Figure 3). First, insulin suppressed adipose lipolysis, lowered hepatic acetyl-CoA content (an allosteric activator of pyruvate carboxylase [PC]), and reduced PC activity and PC flux (17). Second, by inhibiting lipolysis, insulin curtailed glycerol delivery to the liver and reduced conversion of glycerol to glucose (18, 19). Hepatic insulin signaling may establish the transcriptional tone of gluconeogenic enzymes and determine the gluconeogenic capacity of the liver, but the ability of insulin to acutely regulate hepatic glu-
skeletal muscle activates Akt2 (Figure 1). Akt2 activation leads to phosphorylation and inactivation of two RabGTPases, Akt substrate of 160 kDa (AS160, also known as TBC1D4; refs. 20, 21) and TBC1D1 (22), which increase glucose transporter type 4–containing (GLUT4–containing) storage vesicles (GSVs) trafficking to the plasma membrane, cellular glucose transport, and glycogen synthesis. Some recent studies also suggest the presence of a PI3K-independent arm that can promote cleavage of tether containing UBX domain for GLUT4 (TUG), a protein that sequesters GSVs in a perinuclear storage compartment (23–26). Insulin-independent mechanisms also activate muscle glucose uptake. Mice with targeted deletion of the insulin receptor in skeletal muscle have impaired insulin-induced muscle glucose uptake (27) but have normal exercise-induced muscle glucose uptake (28). Muscle contraction activates AMPK, which phosphorylates proteins that regulate GSV translocation (29). AMPK activation is one of many factors that comprise a network of signals that promote glucose uptake in response to exercise but independently of insulin action (recently reviewed in ref. 30).

Figure 2. Mechanisms of insulin resistance.
In the liver, DAG-mediated activation of PKCε impairs hepatic insulin signaling, constraining insulin-stimulated hepatic glycogen synthesis. Hepatic lipid synthesis continues unabated. In the skeletal muscle, DAG-mediated activation of PKCθ impairs muscle insulin signaling, impeding insulin-stimulated muscle glucose uptake and leading to increased glucose delivery to the liver. Exercise can still function to promote glucose uptake. In adipose tissue, cytokine release from ATMs promotes adipose lipolysis and leads to increased release of fatty acids (FAs). This will further drive hepatic lipid synthesis and activate hepatic gluconeogenesis via acetyl-CoA-mediated (Ac-CoA-mediated) activation of PC and glyceral, increasing glucose production via substrate push. IR, insulin receptor; GP, glycogen phosphorylase; GS, glycogen synthase; LPA, lysophosphatidic acid; HL, hepatic lipase; CM-R, chylomicron remnants; VLDL, very low–density lipoprotein; CAM-KII, calmodulin kinase II; IRS1/2, insulin receptor substrate 1/2; βAR, β-adrenergic receptor; CM-TG, chylomicron–triglycerides.
B48-containing (ApoB48-containing) triglyceride-rich chylomicrons that are rapidly cleared. The hydrolysis of triglyceride into fatty acids by lipoprotein lipase (LpL, Figure 1) is a rate-controlling step for cellular lipid uptake from plasma and is highly regulated (recently reviewed in ref. 33). The release of triglyceride from intracellular stores is similarly highly controlled by intracellular lipases (reviewed in ref. 34). While a full discussion of the uptake and release of lipids is beyond the scope of the present review, we review some studies to illustrate how the regulation of LpL activity fits into the broader coordination of energy metabolism. For example, insulin increases expression of LpL in s.c. adipose tissues (35), while insulin resistance in humans is associated with a decrease in s.c. adipose LpL expression (36, 37). Whereas insulin regulates basal LpL expression, a number of other proteins regulate LpL activity (38). As one example, when exercising muscle is compared with nonexercising muscle (e.g., single-leg cycling), there is a PPARδ-regulated induction of angiopoietin like-4 (ANGPLT4, an inhibitor of LpL) in the nonexercising muscle matched with a concurrent AMPK-mediated suppression of ANGPLT4 in the exercising muscle (39). Thus, coordination of LpL activity channels lipids to metabolically active sites.

Ectopic lipid accumulation and insulin resistance

The association between obesity, insulin resistance, and T2D has long been appreciated. 1H MRS studies have demonstrated that intramyocellular lipid (IMCL) content is a much better predictor of muscle insulin resistance than fat mass in healthy, young, sedentary, lean individuals (40) and nonobese, nondiabetic but insulin-resistant adults (41) and children (42), suggesting a potential causal role for IMCL mediator(s) in this process.

Over a half century ago, Randle and colleagues concluded that muscle insulin resistance associated with obesity could be attributed to increased fatty acid oxidation that limits insulin-stimulated glucose utilization (43). The essential tenet of this model was that increased delivery and oxidation of fatty acids leads to accumulation of citrate that inhibits phosphofructokinase, a key enzyme in glycolysis, leading to increases in intramyocellular glucose-6-phosphate and glucose, which thereby impairs glucose utilization (43).
Yet, noninvasive measurements of these metabolites by \(^{13}\)C and \(^{31}\)P MRS studies found that the intramyocellular concentrations of these metabolites were decreased in human muscle during the acute induction of insulin resistance by a lipid infusion, demonstrating that fatty acids impair insulin-stimulated glucose metabolism in muscle by blocking glucose transport into the cell, not through inhibition of glycolysis (44, 45). Similar reductions in glucose transport were observed in insulin-resistant, obese individuals (46); patients with T2D (47); and lean, normoglycemic but insulin-resistant offspring of T2D parents (48). Taken together, these data support the hypothesis that an IMCL metabolite induces insulin resistance by causing defects in insulin-stimulated muscle glucose transport activity (45).

IMCL accumulates when there is a mismatch between lipid oxidation and lipid delivery to the myocyte (Figure 2 and refs. 48, 49). In elderly subjects, skeletal muscle insulin resistance was associated with increased IMCL and a 35% reduction in both mitochondrial oxidative and phosphorylation activity. Age-associated reductions in mitochondrial function may be due to cumulative damage from ROS (50). Supporting this hypothesis, transgenic mice that overexpress a mitochondrial-targeted form of human catalase were protected from mitochondrial oxidative damage associated with aging and were able to maintain normal muscle mitochondrial function, muscle triglyceride/diacylglycerol (DAG) content and insulin action (51). Muscle mitochondrial oxidative and phosphorylation activity were also reduced by approximately 40% in healthy, young, lean, insulin-resistant offspring of patients with T2DM (52, 53). In contrast to aging, these reductions in mitochondrial activity appear to be secondary to reduction in mitochondrial density (54) and may be due in part to diminished expression of LpL in skeletal muscle, which could limit PPAR\(\gamma\)-mediated mitochondrial biogenesis (55). Together, these studies demonstrate the close association between ectopic lipid accumulation and insulin resistance in skeletal muscle, and they highlight the potential role of reduced mitochondrial function in promoting IMCL accumulation.

**Cellular mechanisms of muscle insulin resistance**

IMCL primarily reflects intramyocellular triglyceride content. While IMCL strongly correlates with muscle insulin resistance in sedentary individuals, triglycerides themselves have been disassociated from insulin resistance, suggesting that other lipid species (e.g., DAGs, ceramides, etc.) mediate insulin resistance (56). Numerous studies have delineated the mechanistic links between DAG accumulation and muscle insulin resistance and point specifically to a proximal defect in insulin signaling.

Insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-1–associated P13K activation were acutely impaired in skeletal muscle of lipid-infused humans (45) and rodents (56, 57). In rodents, lipid infusion and high-fat feeding led to transient increases in muscle DAG content (56), resulting in sustained activation of PKC\(\epsilon\) that limited phosphorylation of IRS-1 by IRTK (Figure 2). Lipid infusions in healthy human volunteers similarly increased skeletal muscle DAG and nPKC activation (PKC\(\epsilon\), ref. 58; PKC\(\delta\), ref. 59) and caused muscle insulin resistance. These studies support a mechanistic model in which muscle DAG accumulation activates PKC\(\delta\), which impairs insulin signaling.

The development of muscle insulin resistance can lead to metabolic disease. This has been observed in genetic mouse models of selective muscle insulin resistance due to muscle-specific deletions of the IRTK (27) and GLUT4 (60), which are prone to hepatic steatosis (61) and increased adiposity (27). In young, lean, otherwise healthy humans with skeletal muscle insulin resistance, ingested glucose is not taken up by muscle but instead gets diverted to the liver, where it becomes substrate for hepatic de novo lipogenesis (DNL), increasing liver triglyceride synthesis and plasma triglyceride concentrations, and reducing plasma HDL concentrations (ref. 62 and Figure 4).

**Cellular mechanisms of hepatic insulin resistance**

NAFLD is strongly associated with hepatic insulin resistance. Though different models have been proposed for the development of hepatic insulin resistance (reviewed in ref. 5), a substantial body of work also supports the role of DAG accumulation and PKC\(\epsilon\) activation in impairing hepatic insulin action. Briefly, studies in patients with generalized lipodystrophy demonstrated that ectopic lipid accumulation in liver and skeletal muscle was associated with severe hepatic and muscle insulin resistance, despite the absence of adipose tissue (63). Leptin therapy reduced calorie intake, resolved hepatic steatosis, and improved insulin action (63). Lipodystrophic mice have a similar phenotype, and fat transplantation rescued these mice by allowing a redistribution of lipids from ectopic sites to transplanted adipose tissue and normalization of insulin action (64). Similarly, mice overexpressing LpL in the liver develop hepatic steatosis and liver-specific insulin resistance (65). In rats and mice, short-term, high-fat diets lead to hepatic steatosis and hepatic insulin resistance without muscle lipid accumulation or peripheral insulin resistance. Thus, these studies demonstrate that ectopic lipid in the liver is specifically associated with hepatic insulin resistance and disassociate hepatic insulin resistance from obesity and visceral adiposity.

In fat-fed rats, the increase in hepatic DAG content activates PKC\(\epsilon\), the primary PKC isoform in liver (66, 67). These changes are associated with decreased activation of IRTK (ref. 68 and Figure 2). Lowering PKC\(\epsilon\) expression protected rats from lipid-induced hepatic insulin resistance and preserved IRTK activity, though hepatic DAG and triglyceride content was unchanged (68). Similarly, Prkce–/– mice are protected from diet-induced insulin resistance following one week of high-fat feeding, despite increases in liver lipid content (69). These data support a model for hepatic insulin resistance where the accumulation of hepatic DAG activates PKC\(\epsilon\) and impairs IRTK activation, and demonstrate that PKC\(\epsilon\) activation is necessary for lipid-induced hepatic insulin resistance.

This paradigm has been translated to humans. Kumashiro et al. studied determinants of insulin resistance in a cohort of patients undergoing bariatric surgery (70). Hepatic DAG content and PKC\(\epsilon\) activation were the strongest predictors of insulin sensitivity. In contrast, there was no association between insulin sensitivity and other factors implicated in the pathogenesis of hepatic insulin resistance (e.g., JNK1 activation, ceramide content, etc.). Magkos et al. also demonstrated that hepatic DAG content (but not hepatic ceramide content) was the best predictor of hepatic insulin resistance in obese humans (71).
There are some circumstances in which hepatic steatosis appears disassociated from hepatic insulin resistance. Decreasing expression of comparative gene identification-58 (CGI-58), an activator of adipose triglyceride lipase (ATGL), led to marked hepatic steatosis and an increase in total DAG content without hepatic insulin resistance (72). However, loss of CGI-58 altered the subcellular distribution of DAG and nPKCs; specifically, CGI-58 knockdown prevented DAG accumulation at the plasma membrane, PKCε activation, and the associated impairments in hepatic insulin action (73).

A common single nucleotide polymorphism (rs738409, I48M) in the lipid droplet protein patatin-like phospholipase domain-containing protein 3 (PNPLA3, also called adiponutrin) has been associated with increased hepatic steatosis but not insulin resistance (74). Mice expressing the knock-in mutation develop diet-induced steatosis with normal glucose tolerance (75). This mutation may increase PNPLA3 content on lipid droplets (75) and lead to an increase in triglyceride content, but not other bioactive lipids (i.e., DAG; ref. 76). Thus, instances of apparent disassociation of hepatic steatosis and hepatic insulin resistance may be explained by a better understanding of the subcellular distribution of DAG and nPKCs.

Finally, loss of insulin-mediated Akt activation may not be an absolute requisite for insulin resistance. Coate and colleagues demonstrated that dogs fed a high-fat diet or high-fructose diet for four weeks developed a similar degree of insulin resistance (77). High-fat feeding impaired insulin-stimulated Akt phosphorylation, but a high-fructose diet did not. Instead, high-fructose feeding impaired glucokinase activity and glycogen synthesis. Thus, the typical high-calorie diets consumed by humans may impede hepatic insulin action via multiple pathways.

Ceramides are also bioactive lipid molecules that are implicated in the development of insulin resistance. Increases in hepatic and muscle ceramide content have been associated with insulin resistance.
resistance in rodents (78), and inhibitors of ceramide synthesis can prevent insulin resistance (79, 80). However, a disassociation between ceramide content and tissue insulin resistance has been reported in multiple studies (70, 71, 81), and the underlying mechanism linking ceramides to insulin resistance has not been fully resolved. Recently, two studies examined how a specific ceramide species, C16:0, impedes mitochondrial function, allowing triglyceride accumulation and insulin resistance (82, 83). Though not examined in these studies, it is possible that the reciprocal relationship between C16:0 ceramide and mitochondrial oxidation could also increase DAG, activate nPKCs, and impair insulin signaling.

Adipose insulin resistance

In part, adipose insulin resistance is the inability of insulin to activate adipose glucose transport, promote lipid uptake, and suppress lipolysis (Figure 3). While decreased adipose glucose uptake is demonstrated in both in vivo and in vitro models, the mechanism and metabolic impact of impaired insulin-mediated glucose uptake in adipose tissue is unclear. Insulin-stimulated adipose glucose metabolism is quantitatively minor compared with whole body insulin-stimulated glucose metabolism; however, glucose metabolism within adipocytes exerts extra-adipose actions. For example, loss of adipose GLUT4 in mice does not alter adiposity or weight gain but leads to insulin resistance in skeletal muscle and liver (84). Glucose entry into adipose cells activates carbohydrate response element binding protein (ChREBP), which may impact adipose lipid metabolism (85). Intriguingly, adipose ChREBP expression appears directly related to insulin sensitivity in humans (85). Adipocytes release specific fatty acids that are associated with increased insulin sensitivity, like palmitoleate (86, 87) or monomethyl branched chain fatty acids (88). Recently, ChREBP was implicated in the synthesis of fatty acid esters of hydroxy fatty acids (FAHFAs), which improve glucose tolerance (89). Adipokynes (e.g., leptin, resistin, and adiponectin) also impact systemic insulin sensitivity (90). Increases in leptin and resistin are associated with insulin resistance, while adiponectin is associated with increased insulin sensitivity. Mice lacking adiponectin are prone to hepatic steatosis and hepatic insulin resistance (91, 92). While overexpression of adiponectin in ob/ob mice leads to increased adiposity, the improvement in adipose function lowered adipose inflammation, circulating lipids, and hepatic DAG content and improved hepatic insulin action (93). Thus, WAT exerts systemic effect via the release of substrates (fatty acids, glycerol) and signaling molecules (adipokynes and lipokynes).

Common genetic mutations impact ectopic lipid storage. Recently, polymorphisms in APOC3 were shown to predispose lean, male individuals to NAFLD and insulin resistance (94, 95). These polymorphisms led to approximately 30% higher plasma ApoC3 concentrations and postprandial hypertriglyceridemia through ApoC3’s inhibitory effect on LpL activity, which increased hepatic uptake of chylomicron remnants. Similarly, transgenic mice that overexpress human ApoC3 in the liver had increased hepatic triacylglycerol (TAG)/DAG accumulation when fed a high-fat diet with the activation of hepatic PKCε and the development of hepatic insulin resistance (89).

Multiple factors impede the ability of insulin to suppress adipose lipolysis, including inflammation. Activated adipose tissue macrophages (ATMs) are recruited via chemokine signaling (96, 97) and release cytokines that promote lipolysis. TNFα lowers per ilipin expression, presumably enhancing lipolysis (98, 99). Additionally, TNFα, IL-1β, and IFNγ decrease expression of fat-specific protein 27 (FSP27) (100), which may stabilize lipid droplets by controlling lipase access to triglycerides. Adipose lipolysis is also regulated by other pathways. Some data suggest that hypothalamic insulin may suppress sympathetic nervous system signaling and thereby reduces catecholamine-mediated lipolysis (101–103).

Regulation of hepatic triglyceride synthesis and selective hepatic insulin resistance

A central paradox in the pathogenesis of T2D is the apparent selective nature of hepatic insulin resistance wherein insulin fails to suppress hepatic glucose production, yet continues to stimulate lipogenesis, resulting in hyperglycemia, hyperlipidemia, and hepatic steatosis. Efforts to explain this paradox have focused on finding a branch point in insulin signaling where hepatic glucose and lipid metabolism diverge. Vatner et al. hypothesized that hepatic triglyceride synthesis could be driven by substrate (fatty acids), independent of changes in hepatic insulin signaling (109). They tested this in awake normal rats, high-fat–fed, insulin-resistant rats and insulin receptor 2′-O-methoxyethyl chimeric antisense oligonucleotide–treated rats infused with varying concentrations of lipid and insulin. Rates of fatty acid esterification into hepatic triglyceride were found to be dependent on the rate of fatty acid delivery to the liver and independent of hepatocellular insulin signaling. In contrast, de novo hepatic lipogenesis was insulin dependent and was reduced in rats with defective hepatic insulin signaling. These studies offer a solution to this paradox. The major source of hepatic lipid synthesis, esterification of preformed fatty acids, is primarily dependent on substrate delivery and largely independent of hepatic insulin action (Figure 4).
Monosaccharides act as both substrates for and nutrient regulators of hepatic DNL. In normal subjects, glucose is largely metabolized in skeletal muscle. However, muscle insulin resistance, which occurs early in the course of T2D (47), increases glucose delivery to the liver, where the lipogenic machinery has been primed by chronic hyperinsulinemia (110). Fructose, which is consumed in nearly equal amounts as glucose, can also promote lipogenesis. Both glucose and fructose may also act to regulate hepatic lipogenesis independently of insulin action (Figure 1). Both increase SREBP1c expression even in the absence of insulin (111), though insulin action may be necessary for full SREBP1c processing to realize the maximal conversion of these sugars into lipids (112). But fructose, unlike glucose, is primarily funneled into the liver, providing a substantial carbon substrate for lipogenesis. Human subjects who consumed fructose-containing beverages, in comparison with those consuming isocaloric glucose-containing beverages, developed hyperlipidemia and insulin resistance despite gaining a similar amount of weight (113). Monosaccharides also enlist other transcription factors, including ChREBP (114, 115), PPARα, adipose triglyceride lipase, perilipin A, and lipoprotein lipase (116, 117), to activate lipogenesis. In summary, though insulin potentiates DNL by activating SREBP1c, substrate flux into the liver also impacts hepatic lipid synthesis. Fatty acid flux promotes hepatic lipid synthesis by reesterification, while monosaccharide flux provides both the substrate and the stimulus for lipogenesis. Together, these alternate pathways may promote hepatic lipid synthesis despite the presence of hepatic insulin resistance.

Increased WAT lipolysis also promotes hepatic insulin resistance by increasing hepatic gluconeogenesis. First, lipolysis increases fatty acid delivery to the liver, leading to increased hepatic acetyl-CoA content, which activates PC activity and PC flux (17, 18). Second, WAT lipolysis also increases glycerol delivery to the liver which can promote glucose production by a substrate dependent push mechanism independently of hepatic insulin action (17-19). Both of these processes are independent of insulin signaling in the liver and are dependent on normal insulin signaling in the adipocyte. Inhibiting lipolysis with an ATGL inhibitor lowered rates of hepatic gluconeogenesis in normal chow-fed rats, insulin-resistant high-fat-fed rats, and insulin-resistant rats treated with an antisense oligonucleotide to knock down hepatic and adipocyte IRTK. The importance of intrahepatic DAG and acetyl-CoA in promoting hepatic insulin resistance and increased hepatic gluconeogenesis was also demonstrated in rats treated with either a liver-targeted or controlled release formulation of a mitochondrial protonophore (81, 118). In both cases, sublethal increases in hepatic mitochondrial inefficiency reduced hepatic DAG and acetyl-CoA content with marked improvement in hepatic insulin signaling and reductions in rates of hepatic gluconeogenesis and fasting hyperglycemia in diabetic animals. These studies inform a model that recognizes a plurality in insulin’s regulation of hepatic glucose and lipid metabolism. Insulin acts directly via hepatic insulin signaling to stimulate net hepatic glycogen synthesis and hepatic DNL, but insulin’s extrahepatic action to suppress lipolysis in WAT is critical for maintaining normal carbohydrate and lipid metabolism by inhibiting hepatic gluconeogenesis and curtailing hepatic esterification of fatty acids to triglyceride.

Decreasing ectopic lipid accumulation reverses insulin resistance and T2D

Weight loss addresses the root causes of insulin resistance and is an essential goal for all patients with ectopic lipid deposition, insulin resistance, and T2D. Modest weight loss can reduce hepatic lipid content, normalize hepatic insulin sensitivity (119), and “reverse” T2D (119, 120). Aerobic exercise also improves insulin sensitivity. Skeletal muscle glucose transport is activated by insulin-independent mechanisms in response to exercise and aerobic conditioning. Exercise is a potent therapy for patients with T2D, as it bypasses the block in insulin signaling to enhance muscle glucose uptake and potentially reestablish the normal disposal of dietary glucose into muscle glycogen. In insulin-resistant subjects, a single session of aerobic exercise augmented muscle glucose transport activity and insulin-stimulated muscle glycogen synthesis (48). Even short (6-minute) bursts of exercise prior to meals can significantly improve the diurnal glucose excursion (121). Further evidence in support of the key role of substrate in promoting increased hepatic DNL was demonstrated by a study that found that a single bout of elliptical training resulted in increased post-prandial muscle glycogen synthesis and reduced hepatic DNL without altering plasma glycogen concentrations in healthy, young, lean individuals with selective muscle insulin resistance (122).

Conclusions

Calorie imbalance, promoted by our modern, toxic environment, results in ectopic lipid accumulation in liver and skeletal muscle, which impedes insulin action in these tissues. Subsequent adipocyte dysfunction promotes macrophage infiltration and increases lipolysis, further impairing hepatic carbohydrate and lipid metabolism in several ways. First, increased fatty acid flux promotes fatty acid esterification and hepatic triglyceride synthesis, exacerbating hepatic steatosis, hepatic insulin resistance, and hypertriglyceridemia (Figure 4). Fatty acid delivery also increases hepatic acetyl-CoA, which allosterically activates PC, while the increased delivery of glycerol further increases hepatic gluconeogenesis (Figure 3). These hepatic processes are all mostly substrate driven and independent of insulin signaling in the liver but dependent on insulin signaling in WAT. In contrast, hepatic glycogen synthesis and hepatic DNL are dependent on both substrate (glucose and fructose) delivery to liver and the direct effects of insulin signaling in liver and are reduced with hepatic insulin resistance and insulin deficiency. While increased β cell function and hyperinsulinemia initially try to compensate for these dysregulated processes, glucolipotoxicity and genetic factors lead to β cell failure and progression to T2D.

Our understanding of the molecular basis of insulin resistance and increased hepatic gluconeogenesis will inform our approach to the global diabetes epidemic. Policies and education that encourage better nutrition and minimize sedentary behavior will promote default behaviors that could lower the prevalence of T2D (123). But new drugs are also required. In this regard, FGF-21 has been shown to be effective in reducing hepatic steatosis and reversing insulin resistance in rodents (124) and is now in clinical trials (125). Acetyl-CoA carboxylase inhibitors decrease hepatic lipogenesis, increase fatty acid oxidation, and show promise in reversing fatty liver in rodent models of NAFLD and T2D.
(126–128). Proof-of-concept studies in rodent models of NALFD and T2D demonstrate that mildly increasing hepatic mitochondrial efficiency can safely reverse hypertriglyceridemia, ectopic lipid-induced (DAG/nPKC) liver and muscle insulin resistance, steatohepatitis, liver fibrosis, and diabetes, offering a novel therapeutic target for T2D and nonalcoholic steatohepatitis (NASH) (81, 118, 129). This knowledge and understanding gained over the past several decades into the pathogenesis of insulin resistance may avert the looming epidemics of diabetes and NALFD/NASH and ensure a healthier future for subsequent generations (130).

Acknowledgments
Supported by grants from the NIH (DK-40936, DK-49230, DK-085638, DK-059635, and DK-45735) and Veterans Administration (I01 BX000901).

Address correspondence to: Varman T. Samuel or Gerald I. Shulman, Yale University School of Medicine, PO Box 208020, New Haven, Connecticut 06520, USA. Phone: (203) 937-3848. E-mail: varman.samuel@yale.edu (V.T. Samuel) or gerald.shulman@yale.edu (G.I. Shulman).

The Journal of Clinical Investigation

REVIEW


